Findings

What do systematic reviews say?

2,191 questions · 2,354 findings · 362 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 323 · 13.7%GRADE not reported 382 · 16.2%Very low 555 · 23.6%Low 597 · 25.4%Moderate 345 · 14.7%High 152 · 6.5%

Whole‐facility changes: Home‐like models vs traditional environment

Depression Revised Memory and Behaviour Problems Checklist (RMBPC) and Mood Scale Score (MSS) (lower scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
406 participants
Very low

Whole‐facility changes: Home‐like models vs traditional environment

Activities of daily living · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
499 participants
Very low

Whole‐facility changes: Home‐like models vs traditional environment

Serious adverse effects Physical restraints, reported as percentage points (lower = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

It is very uncertain whether whole‐facility changes: Home‐like models changes serious adverse effects Physical restraints, reported as percentage… compared with traditional environment (very low certainty).

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74449 participants
Very low

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Berotralstat vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Low

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Cemented vs uncemented hemiarthroplasty

Activities of daily living · adults with displaced and undisplaced hip fractures

1 finding from 1 review

Arthroplasties for hip fracture in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1275 participants
Moderate

Total hip arthroplasty vs hemiarthroplasty

Mobility · adults with displaced and undisplaced hip fractures

1 finding from 1 review

Arthroplasties for hip fracture in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 83 participants
Low

Any intervention vs steroid alone or plus levofloxacin

Proportion of eyes in which SEI had developed within 21 days of treatment (lower is favored) · epidemic keratoconjunctivitis

It is very uncertain whether any intervention changes proportion of eyes in which SEI had developed within 21 days of… compared with steroid alone or plus levofloxacin (very low certainty).

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
RR 0.08 [0.01, 0.55]
2 studies · 69 participants
Very low

Any intervention vs steroid alone or plus levofloxacin

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

The review found no eligible studies for this question.

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical steroid vs artificial tears

Proportion of eyes in which SEI had developed within 21 days of treatment (lower is favored) · epidemic keratoconjunctivitis

It is very uncertain whether topical steroid changes proportion of participants in whose eyes SEI had developed within 21… compared with artificial tears (very low certainty).

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
RR 2.2 [0.89, 5.41]
1 study · 50 participants
Very low

Topical steroid vs artificial tears

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

The review found no eligible studies for this question.

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Any intervention vs artificial tears or saline

Proportion of participants in whose eyes SEIs had developed within 30 days of treatment initiation (lower is favored) · epidemic keratoconjunctivitis

It is very uncertain whether any intervention changes proportion of participants in whose eyes SEIs had developed within… compared with artificial tears or saline (very low certainty).

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
RR 0.24 [0.1, 0.56]
2 studies · 77 participants
Very low

Any intervention vs artificial tears or saline

Proportion of initially unaffected fellow eyes that had signs/symptoms of infection within 7 days of onset of signs/symptoms in the first eye (lower is favored) · epidemic keratoconjunctivitis

The review found no eligible studies for this question.

1 finding from 1 review

Topical pharmacologic interventions versus placebo for epidemic keratoconjunctivitis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found